YOUR BUSINESS AUTHORITY

Springfield, MO

Log in Subscribe

Novo Nordisk's Wegovy approved for liver disease

Posted online

The U.S. Food and Drug Administration has given approval to Novo Nordisk for its Wegovy obesity drug to be used to treat serious liver disease.

The company got the OK for the treatment of metabolic dysfunction-associated steatohepatitis in adults with moderate to advanced liver fibrosis.

Novo Nordisk's shares were up nearly 5% on the news.

Read more from CNBC.

Comments

No comments on this story |
Please log in to add your comment
Editors' Pick
Annual downtown holiday events combine for Nov. 21 celebration

Organizers hope to bolster client traffic to center city businesses.

Most Read
SBJ.net Poll
How often do you use artificial intelligence for your business?

*

View results

Update cookies preferences